CDX-301
As of the edition of 20 October 2026, CDX-301 is a drug: stopped in 2023; acts on FLT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Unknown
- Registered trials
- 14, 4 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Immune system; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of CDX-301.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | P36888 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 3 | 4 | 0 |
| Phase 2 | 7 | 3 | 0 | 4 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Celldex Therapeutics | Lead sponsor of trials | 2011 to now |